Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Following its 19 June agreement with Nurix Inc. to collaborate on protein-degradation therapies for cancer and other indications,